# Disease-Modifying Antirheumatic Drugs (DMARDs)

Dr. Mohammed Al-Sbou Professor of clinical Pharmacology Faculty of Medicine, Mutah University 

- Most common: Rheumatoid arthritis (RA)
- Less common of inflammatory arthritis:
- Juvenile idiopathic arthritis (JIA) =>mostly allected =>children.
- Spondyloarthritis (ankylosing spondylitis, psoriatic arthritis, arthritis associated with inflammatory bowel disease)
- Joint pains (arthralgia) is common in connective tissue diseases (SLE, scleroderma)
- Endocrine diseases (hypo- & hyperthyroidism) (T3, T4, T5H)

#### Rheumatoid arthritis (RA)

- is an autoimmune disease that can cause chronic inflammation of joints & other areas of the body
- > Fatigue (Inflammation signs)
- > Joint pain, tenderness, swelling, redness, warmth
- > Stiffness of joints, particularly worse in the morning
- > Many joints affected (polyarthritis) Shoulder => Elbow => Wrist => Fingers
- Both sides of the body affected (symmetric)

Rheumatoid arthritis usually affects joints symmetrically (on both sides equally), may initially begin in a couple of joints only, and most frequently attacks the wrists, hands, elbows, shoulders, knees and ankles







#### Patient's priority is relief of joint pain, swelling & stiffness

> There is no cure for arthritis

Successful treatment requires multidisciplinary approach with DMARDs, pain management (NSAIDs) & low-dose corticosteroids, physiotherapy

- it's the known clinical approach to cure the patients with best possible way that can be accomblished. by Using DMARD's + NSAID's + Cortico + Physiotherapy

Magic drug ≥ but associated w1 many App



- > Are immunemodulators that restore more normal immune environment within joint synovium
- They are used primarily for rheumatic disorders in which inflammatory disease does not respond to cylcooxygenase inhibitors



- Slow course of disease => Depends on the Scientify of the disease.
- Can cause remission
- Prevent further destruction of joints & involved tissues
- Early initiation of DMARDs is recommended to control signs & symptoms and to limit joint damage

- If you can't fix it with drugs and physiotherapy (too severe), the pateint will have to do joint replacement.



لما سارة قالت ازا ركبتي موتتني باخذ دوا

- Immunosuppressants:
  - (Methotrexate, leflunomide, azathioprine, ciclosporin, cyclophosphamide)
- > Hydroxychloroquine => can be used w/ mill to moderate cases.
- > D-Penicillamine
- > Gold Salts
- > Biological agents: cytokine modulators

IV infusion Neck Hospital submission.



- They have <u>a long onset of action</u>, require <u>2-6 months</u> for full therapeutic response
- Choice of DMARDs:
  - No one DMARD is efficacious and safe in every patient

 Start with traditional small molecules agents, such as methotrexate or hydroxychloroquine (efficacious, well tolerated, well-known side-effects profiles)



#### لا تعيدها = LA TIEDHA

- Inadequate response, newer drugs such as leflunomide, anakinra, TNF inhibitors (etanercept, infliximab, adalimumab)
- Combination therapies are both safe & effective
- In most cases, methotrexate is combined with one DMARDS (TNF inhibitors)

nethotrexate

- Combination of MTX plus rituximab



It is an immunosuppressant (RA is autoimmune disease)

First line treatment in RA & PA

Used alone or in combination therapy in patients with moderate to severe rheumatoid or psoriatic arthritis who have not responded to NSAIDs

It acts by competitive inhibition of enzyme <u>dihydrofolate reductase</u>

Inhibits purine synthesis

### **<u>1. Methotrexate</u>**

Slows appearance of new erosions within involved joints on radiographs > Response to MTX occurs sooner than with other agents within 3 to 6 weeks In high doses, used in solid & haematological malignancies Doses in RA are lower than those needed in cancer chemotherapy, 7.5 mg once a week orally

### **<u>1. Methotrexate</u>**

#### Adverse effects:

- Most common: Mouth ulcer & nausea
- Bone marrow toxicity: Pancytopenia (WBCs)
- Hepatic toxicity: Liver cirrhosis with long-term use
- Acute pneumonia-like syndrome, after chronic administration
- It is teratogenic
- Taking leucovorin (folinic acid) reduces severity of side effects
- Monitoring side effects: CBC, liver enzymes, signs of infections

## 2. Leflunomide

> It is an immunomodulatory agent that causes cell arrest of T lymphocytes through its action on dihydroorotate dehydrogenase (DHODH) Inhibits pyrimidine synthesis & prevent Tcell proliferation which is thought to be important in pathogenesis of RA

### 2. Leflunomide

- Reduces pain, inflammation & slow progression of structural damage
- Can be used in monotherapy as alternative to MTX or an addition to MTX
- > Pharmacokinetics:
- Administered orally
- Long half-life of 14 to 18 days

### 2. Leflunomide

#### > Adverse effects:

- Most common: headache, diarrhea, nausea
- Weight loss, allergic reactions (skin rash, alopecia)
- Teratogenic, is contraindicated during pregnancy
- Should be used with caution in liver disease

#### 3. Hydroxychloroquine

#### > Advaquenil

- Is used in <u>treatment of malaria</u> (antimalaria actions)
- > Used in early & mild RA
- When used alone, it dose not slow joint damage, it is often used in combination with MTX
- > Accumulate within lymphocytes, macrophages & inhibit phagocyte function

### **<u>3. Hydroxychloroquine</u>**

- It is used for arthralgia associated connective tissue diseases e.g. SLE
- > They cause serious adverse effects:
  - Retinal damage (rare)
  - Skin discoloration
  - Alopecia
  - Bleaching of hear
  - GI upset

### 4. D-Penicillamine

- It reduces rheumatoid factor & concentration of immune complexes in plasma & synovial fluids
- > Rarely used
- Serious side effects: GI upset, impairment of taste, dermatological, nephritis, aplastic anemia, allergic reactions

**Biological Therapies** (Cytokine modulators)

- Interleukin-1b (IL-1b) & tumor necrosis factoralpha (TNF-alpha) are pro-inflammatory cytokines involved in pathogenesis of RA
- Drug antagonists of cytokines are effective in treating RA

### **Cytokine modulators**

When secreted by synovial macrophages, they stimulate synovial cells to proliferate & synthesize collagenase, thereby degrading cartilage, stimulating bone resorption

> TNF inhibitors decrease signs & symptoms, reduce progression of structural damage, improve physical function Clinical response within 2 weeks > TNF inhibitors increase risk of infections (TB, sepsis), fungal infections, pancytopenia Live vaccinations should be avoided Cautious in patients with heart failure

 TNF- alpha inhibitors: (Etanercept, infliximab, adalimumab)
IL-1 receptor antagonist: anakinra
Monoclonal antibody: rituximab

## 1. Etanercept (Enbrel)

- > Genetically engineered fusion protein
- > Used alone or in combination with MTX
- Is given in moderate to severe RA, ankylosing spondylitis, psoriatic arthritis
- Mechanism of action:
- It binds to TNF molecules & prevents them from binding to cell surface TNF receptors
- Is given Sc twice a week, (half-life115 hrs)
- Side effects: local inflammation at site of injection

## 2. Infliximab (Remicade)

- Is monoclonal antibody that binds to TNF-alpha, thereby neutralizing that cytokine
- > Approved for treatment of RA, Crohn's disease & ulcerative colitis, psoriasis, ankylosing spondylitis
- Not indicated for use alone, because of development of anti-infliximab antibodies
- It is often used in combination with MTX, in patients who had inadequate response to MTX
- > Is infused IV over 2 hrs => needes Hospital admission
- Half life 9.5 days

#### Adverse effects:

- Pancytopenia: leukopenia, neutropenia, thrombocytopenia
- Infusion reactions: fever, chills, pruritus, urticaria
- May predispose to life-threatening infections

### 3. Anakinra (kineret)

Is an IL-1 receptor antagonist

- It binds to IL-1 receptor, thus preventing IL-1 action
- Is used alone or in combination with other DMARDs in patients who failed to response to DMARDs

#### > Is given Sc

It causes neutropenia

### 4. Rituximab - last option!

- Monoclonal antibody against CD20 antigen found on surface of B lymphocytes, resulting in B-cell depletion
- B cells in RA causes activation of T lymphocytes, producing of autoantibodies (anti-CCP cyclic citrullinated peptide antibody), RF & TNF alpha, IL-1
- Used in severe RA with no response to TNF inhibitors
- Is given by IV infusion needs hospital submission
- Side effects: infusion reaction (urticaria, hypotension, angioedema)

#### Intra-articular injection of corticosteroids

**Hide Behind Dex ONE** 

- Hydrocortisone, prednisolone & dexamethasone
- Benefit from one injection may <u>last many weeks</u>
- Aseptic precautions for introducing infection



#### Intra-articular injection of corticosteroids

 Too frequent injections may promote joint damage by removing protective limitation conferred by pain
Injections in <u>a single joint</u> would not exceed three per year

#### Role of systemic corticosteroids

- Use for <u>systemic corticosteroids</u> is reluctance because of <u>its adverse effects</u>
  In extreme severity, high dose prednisolone (20- 40 mg/d) very effectively suppress inflammation
- Where DMARDs have failed or produced intolerable adverse effects
  - e.g. prednisolone 7.5 mg once daily orally

### **Different ways of using DMARDs**

- Drugs may be administered in sequence (to find most effective)
- Alternatively, up to three DMARDs may be given in combination, with drugs added progressively or all started at same time
- Some patients fail to all the standard treatments, they may benefit from long-term maintenance on prednisolone (2- 4 years)